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South African guidelines on venous 
thromboembolism
To the Editor: We commend the excellent work by Jacobson 
et al. on behalf of the South African Society of Thrombosis 
and Haemostasis in producing a very necessary set of local 
guidelines on the management of venous thromboembolism 
(VTE).1 VTE is a major cause of morbidity and mortality, as 
highlighted recently by the United States Surgeon General.2 
One important nuance worth noting, however, is the fact 
that warfarin may be started together with low-molecular-
weight heparin (LMWH) on day 1 of anticoagulation, and 
is supported by recent guidelines by the British Committee 
for Standards in Haematology and the American College of 
Chest Physicians (ACCP) who both agree that LMWH and 
warfarin should be started on the same day.3,4 The ACCP 
gives this recommendation their highest level of evidence, 
namely 1A. Evidence for this suggestion includes data from 
a randomised trial by Mohiuddin et al. showing decreased 
cost and morbidity in the group started earlier on warfarin.5 
Leroyer et al. and Gallus et al. have both also shown decreased 
duration of hospitalisation with earlier initiation of warfarin.6,7 
The ACCP also recommends that the duration of LMWH 
should be for a minimum of 5 days v. the 7 days suggested by 
Jacobson et al. This is in part based on at least one randomised 
trial showing similar efficacy in both arms.8 Although this 
may only result in a total difference of 4 doses of LMWH per 
patient, the long-term cost implications may be significant. 
Lastly, noting the narrow therapeutic window of warfarin, we 
believe that it is important to consider major risk factors for 
bleeding on anticoagulants, such as increased age, uncontrolled 
hypertension, alcohol, use of non-steroidal anti-inflammatory 
drugs, liver disease and peptic ulcer disease, before initiating 
therapy.9,10
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Professor Jacobson replies: On behalf of the authors, I thank 
Webb et al. for their valuable comments.
The initiation of anticoagulation with LMWH and delaying 
warfarin was done knowingly for the following reason: South 
Africa has a nursing crisis aggravated in the State sector where 
LMWH is often only dispensed as a Schedule 7 medication. 
This leads to delays in patients receiving their LMWH. In our 
experience, numerous patients are therefore given warfarin, 
and LMWH is only given by nursing staff 24 - 48 hours 
thereafter. As there is a serious theoretical concern that patients’ 
thromboses – especially those with Protein S deficiencies – will 
be exacerbated, there was consensus that warfarin should only 
be started after the clinician was convinced that the LMWH 
had actually been injected rather than prescribed.
Regarding LMWH duration for a minimum of 5 days v. 
7 days: this actually depends on when the patient is fully 
mobile, which we believe is far more important than looking at 
empirical days, especially as numerous patients are discharged 
early from hospital to recover at home.
Lastly, we fully agree that, when commencing any patient 
on anticoagulation, the risk/benefit needs to be assessed 
and individualised in relation to any contraindications for 
anticoagulation.
Olfactory reference syndrome in  
DSM-V
To the Editor: We read with interest Dr A Lawrence’s recent 
SAMJ case report of a young man who presented with 
persistent preoccupation with personal body odour in the 
absence of any physical abnormalities.1
Dr Lawrence does not explicitly consider a diagnosis 
of olfactory reference syndrome (ORS). This condition, 
characterised by a preoccupation with the idea that one’s 
body odour is foul or offensive to others, may be part of the 
differential diagnosis in patients with psychotic disorders 
(who may have olfactory hallucinations), in patients with 
obsessive-compulsive disorder (who may have concerns about 
contamination, and wash or clean repeatedly) and in patients 
with a social phobia spectrum disorder (who may have severe 
social anxiety because of fears of causing offence).
One of the reasons why ORS was not included in the 
differential diagnoses is that it is not formally included in the 
Diagnostic and Statistical Manual, 4th edition (DSM-IV). The 
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